Replies to post #173196 on Biotech Values

[DewDiligence]

FDA approves GSK’s Tanzeum (albiglutide), a weekly GLP-1 agonist for type-2 diabetes:

http://finance.yahoo.com/news/gsk-receives-us-approval-once-182600617.html

The product is administered subcutaneously with a (thin) 29-gauge needle.

Today was the (extended) PDUFA date. In the EU, this drug is approved by the CHMP under the brand name, Eperzan, but it has not yet been rubber-stamped for marketing by the EU Commission (#msg-96353948).